Corcept Therapeutics Incorporated (CORT)

NASDAQ: CORT · IEX Real-Time Price · USD
24.98
+0.04 (0.16%)
Dec 2, 2022 4:00 PM EST - Market closed
0.16%
Market Cap 2.68B
Revenue (ttm) 397.62M
Net Income (ttm) 116.80M
Shares Out 107.13M
EPS (ttm) 1.00
PE Ratio 24.98
Forward PE 23.75
Dividend n/a
Ex-Dividend Date n/a
Volume 301,902
Open 24.82
Previous Close 24.94
Day's Range 24.67 - 25.16
52-Week Range 15.83 - 30.14
Beta 0.55
Analysts Buy
Price Target 32.81 (+31.3%)
Earnings Date Nov 3, 2022

About CORT

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients wi... [Read more]

Industry Pharmaceuticals
Founded 1998
CEO Joseph Belanoff
Employees 238
Stock Exchange NASDAQ
Ticker Symbol CORT
Full Company Profile

Financial Performance

In 2021, CORT's revenue was $365.98 million, an increase of 3.42% compared to the previous year's $353.87 million. Earnings were $112.51 million, an increase of 6.13%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 32.81, which is an increase of 31.35% from the latest price.

Price Target
$32.81
(31.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

2 weeks ago - Zacks Investment Research

UTHR vs. CORT: Which Stock Should Value Investors Buy Now?

UTHR vs. CORT: Which Stock Is the Better Value Option?

Other symbols: UTHR
3 weeks ago - Zacks Investment Research

Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss

Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022.

4 weeks ago - Zacks Investment Research

Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of 30.43% and 5.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe...

1 month ago - GlobeNewsWire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on No...

1 month ago - GlobeNewsWire

These 3 Stocks Are Winning the Bear Market -- Here's How

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

Other symbols: CPRXVRTX
1 month ago - The Motley Fool

Corcept (CORT) Thrives on Korlym, Overdependence a Concern

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

1 month ago - Zacks Investment Research

7 Under-the-Radar Stocks With 100% Upside Potential

The markets have delivered one of the worst years in the past several decades. As a result, investors are left searching for under-the-radar stocks that have been passed over due to all the bad news.

Other symbols: AMRAZPNELFPLMRPSNWWE
1 month ago - InvestorPlace

Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS

Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.

1 month ago - Zacks Investment Research

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe...

1 month ago - GlobeNewsWire

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp...

2 months ago - Newsfile Corp

Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

2 months ago - Zacks Investment Research

2 Top Biotech Stocks Defying the Bear Market

Both could see record sales throughout the next few years.

Other symbols: AXSM
2 months ago - The Motley Fool

2 Growth Stocks That Are Beating Amazon Without Breaking a Sweat

They're both cornering specialized markets and growing aggressively in the process.

Other symbols: JAZZ
3 months ago - The Motley Fool

Corcept (CORT) Down 8.3% Since Last Earnings Report: Can It Rebound?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

ASRT or CORT: Which Is the Better Value Stock Right Now?

ASRT vs. CORT: Which Stock Is the Better Value Option?

Other symbols: ASRT
3 months ago - Zacks Investment Research

JAZZ or CORT: Which Is the Better Value Stock Right Now?

JAZZ vs. CORT: Which Stock Is the Better Value Option?

Other symbols: JAZZ
3 months ago - Zacks Investment Research

Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y

Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.

3 months ago - Zacks Investment Research

Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates

Corcept (CORT) delivered earnings and revenue surprises of -4% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe...

4 months ago - GlobeNewsWire

Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?

Here is how Corcept Therapeutics (CORT) and Alkermes (ALKS) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on A...

4 months ago - GlobeNewsWire

3 Biotech Stocks Outperforming a Bear Market

These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy. The post 3 Biotech Stocks Outperforming ...

Other symbols: AMGNREGN
4 months ago - InvestorPlace

Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns

Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well.

4 months ago - Zacks Investment Research